RPRX logo

Royalty Pharma (RPRX) EBITDA

Annual EBITDA

$1.56 B
-$330.95 M-17.54%

December 31, 2024

Summary

Performance

1-Year Change

-17.54%

3-Year Change

+8.81%

5-Year Change

-43.49%

15-Year Change

-4.15%

RPRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.68%
RPRX annual EBITDA is higher than 95.68% of companies in Healthcare sector

High & Low

All-time High

$2.75 B
RPRX annual EBITDA is currently -43.49% below its historical high of $2.75 billion

3-Year Low

$423.69 M
RPRX annual EBITDA is currently +267.32% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
RPRX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
RPRX next annual earnings announcement has not yet been scheduled

OtherRPRXprofitabilitymetrics:

Annual Revenue

$2.26 B
RPRX annual revenue is $2.26 billion

Annual Net Income

$858.98 M
RPRX annual net profit is $858.98 million

Annual EBIT

$1.56 B
RPRX annual earnings before interest & taxes is $1.56 billion

Annual EPS

$1.91
RPRX annual earnings per share is $1.91

Quarterly EBITDA

$400.11 M
-$472.75 M-54.16%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-47.69%

3-Year Change

-47.69%

5-Year Change

-47.69%

RPRX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.19%
RPRX quarterly EBITDA is higher than 95.19% of companies in Healthcare sector

High & Low

All-time High

$1.52 B
RPRX quarterly EBITDA is currently -73.60% below its historical high of $1.52 billion

3-Year Low

-$563.08 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
RPRX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
RPRX next earnings announcement is scheduled for May 9, 2025

OtherRPRXprofitabilitymetrics:

Quarterly Revenue

$593.64 M
RPRX quarterly revenue is $593.64 million

Quarterly Net Income

$208.21 M
RPRX quarterly net profit is $208.21 million

Quarterly EBIT

$400.11 M
RPRX quarterly earnings before interest & taxes is $400.11 million

Quarterly EPS

$0.35
RPRX quarterly earnings per share is $0.35

TTM EBITDA

$1.56 B
-$364.73 M-18.99%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-17.54%

3-Year Change

-17.54%

5-Year Change

-17.54%

RPRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.35%
RPRX TTM EBITDA is higher than 95.35% of companies in Healthcare sector

High & Low

All-time High

$2.99 B
RPRX TTM EBITDA is currently -47.90% below its historical high of $2.99 billion

3-Year Low

$423.69 M
RPRX TTM EBITDA is currently +267.32% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
RPRX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
RPRX next earnings announcement is scheduled for May 9, 2025

OtherRPRXprofitabilitymetrics:

TTM Revenue

$2.26 B
RPRX TTM revenue is $2.26 billion

TTM Net Income

$858.98 M
RPRX TTM net profit is $858.98 million

TTM EBIT

$1.56 B
RPRX TTM earnings before interest & taxes is $1.56 billion

TTM EPS

$1.80
RPRX TTM earnings per share is $1.80

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$1.56 B
RPRX annual EBITDA is $1.56 billion

Annual Net Income

$858.98 M
RPRX annual net profit is $858.98 million

Annual Interest Expense

$225.51 M
RPRX annual interest expense is $225.51 million

Annual Income Tax

$0.00
RPRX annual income tax is $0.00

Annual D&A

$0.00
RPRX annual depreciation & amortization is $0.00

RPRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-17.5%-47.7%-17.5%
3 y3 years+8.8%-47.7%-17.5%
5 y5 years-43.5%-47.7%-17.5%

RPRX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-17.5%+267.3%-54.2%+171.1%-19.0%+267.3%
5 y5-year-43.5%+267.3%-73.6%+171.1%-47.9%+267.3%
alltimeall time-43.5%+267.3%-73.6%+171.1%-47.9%+267.3%

Royalty Pharma EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$1.56 B(-17.5%)
$400.11 M(-54.2%)
$1.56 B(-19.0%)
Sep 2024
-
$872.86 M(+258.6%)
$1.92 B(+57.9%)
Jun 2024
-
$243.39 M(+509.1%)
$1.22 B(-11.3%)
Mar 2024
-
$39.96 M(-94.8%)
$1.37 B(-27.3%)
Dec 2023
$1.89 B(+345.4%)
$764.84 M(+355.0%)
$1.89 B(+237.4%)
Sep 2023
-
$168.11 M(-57.8%)
$559.36 M(-15.1%)
Jun 2023
-
$398.29 M(-28.4%)
$658.64 M(-17.6%)
Mar 2023
-
$556.04 M(-198.8%)
$798.92 M(+88.6%)
Dec 2022
$423.69 M(-70.4%)
-$563.08 M(-310.6%)
$423.69 M(-61.2%)
Sep 2022
-
$267.39 M(-50.4%)
$1.09 B(-0.4%)
Jun 2022
-
$538.56 M(+197.9%)
$1.10 B(-22.1%)
Mar 2022
-
$180.82 M(+69.9%)
$1.41 B(-1.5%)
Dec 2021
$1.43 B
$106.44 M(-60.9%)
$1.43 B(-17.5%)
DateAnnualQuarterlyTTM
Sep 2021
-
$271.92 M(-68.0%)
$1.73 B(-18.3%)
Jun 2021
-
$849.91 M(+320.6%)
$2.12 B(+10.9%)
Mar 2021
-
$202.06 M(-50.7%)
$1.92 B(+1.8%)
Dec 2020
$1.88 B(-31.7%)
$410.27 M(-38.0%)
$1.88 B(-37.0%)
Sep 2020
-
$661.49 M(+3.1%)
$2.99 B(+5.2%)
Jun 2020
-
$641.90 M(+281.1%)
$2.84 B(+15.8%)
Mar 2020
-
$168.41 M(-88.9%)
$2.45 B(-10.9%)
Dec 2019
$2.75 B(+50.4%)
$1.52 B(+194.5%)
$2.75 B(+122.4%)
Sep 2019
-
$514.62 M(+102.9%)
$1.24 B(+71.1%)
Jun 2019
-
$253.67 M(-46.0%)
$723.63 M(+54.0%)
Mar 2019
-
$469.96 M
$469.96 M
Dec 2018
$1.83 B(+12.8%)
-
-
Dec 2017
$1.62 B
-
-

FAQ

  • What is Royalty Pharma annual EBITDA?
  • What is the all time high annual EBITDA for Royalty Pharma?
  • What is Royalty Pharma annual EBITDA year-on-year change?
  • What is Royalty Pharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Royalty Pharma?
  • What is Royalty Pharma quarterly EBITDA year-on-year change?
  • What is Royalty Pharma TTM EBITDA?
  • What is the all time high TTM EBITDA for Royalty Pharma?
  • What is Royalty Pharma TTM EBITDA year-on-year change?

What is Royalty Pharma annual EBITDA?

The current annual EBITDA of RPRX is $1.56 B

What is the all time high annual EBITDA for Royalty Pharma?

Royalty Pharma all-time high annual EBITDA is $2.75 B

What is Royalty Pharma annual EBITDA year-on-year change?

Over the past year, RPRX annual EBITDA has changed by -$330.95 M (-17.54%)

What is Royalty Pharma quarterly EBITDA?

The current quarterly EBITDA of RPRX is $400.11 M

What is the all time high quarterly EBITDA for Royalty Pharma?

Royalty Pharma all-time high quarterly EBITDA is $1.52 B

What is Royalty Pharma quarterly EBITDA year-on-year change?

Over the past year, RPRX quarterly EBITDA has changed by -$364.73 M (-47.69%)

What is Royalty Pharma TTM EBITDA?

The current TTM EBITDA of RPRX is $1.56 B

What is the all time high TTM EBITDA for Royalty Pharma?

Royalty Pharma all-time high TTM EBITDA is $2.99 B

What is Royalty Pharma TTM EBITDA year-on-year change?

Over the past year, RPRX TTM EBITDA has changed by -$330.95 M (-17.54%)